Improvement of survival after hematopoietic stem cell transplantation and trends at a pediatric transplantation center; a three-decade journey
Corresponding Author
Gülay Sezgin
Division of Pediatric Oncology & Pediatric BMT Unit, Çukurova University Medical School, Adana, Turkey
Correspondence
Gülay Sezgin, Çukurova University Medical School, Division of Pediatric Oncology/Pediatric BMT Unit, Balcalı Hospital, 01030 Sarıçam, Adana, Turkey.
Email: [email protected]
Search for more papers by this authorYasemin Sofu Öner
Department of Pediatrics, Çukurova University Medical School, Adana, Turkey
Search for more papers by this authorGül İnan
Division of Pediatric Oncology & Pediatric BMT Unit, Çukurova University Medical School, Adana, Turkey
Search for more papers by this authorİlker Ünal
Department of Biostatistics, Çukurova University Medical School, Adana, Turkey
Search for more papers by this authorAyşe Özkan
Division of Pediatric Oncology & Pediatric BMT Unit, Çukurova University Medical School, Adana, Turkey
Search for more papers by this authorSerhan Küpeli
Division of Pediatric Oncology & Pediatric BMT Unit, Çukurova University Medical School, Adana, Turkey
Search for more papers by this authorİbrahim Bayram
Division of Pediatric Oncology & Pediatric BMT Unit, Çukurova University Medical School, Adana, Turkey
Search for more papers by this authorAtila Tanyeli
Division of Pediatric Oncology & Pediatric BMT Unit, Çukurova University Medical School, Adana, Turkey
Search for more papers by this authorCorresponding Author
Gülay Sezgin
Division of Pediatric Oncology & Pediatric BMT Unit, Çukurova University Medical School, Adana, Turkey
Correspondence
Gülay Sezgin, Çukurova University Medical School, Division of Pediatric Oncology/Pediatric BMT Unit, Balcalı Hospital, 01030 Sarıçam, Adana, Turkey.
Email: [email protected]
Search for more papers by this authorYasemin Sofu Öner
Department of Pediatrics, Çukurova University Medical School, Adana, Turkey
Search for more papers by this authorGül İnan
Division of Pediatric Oncology & Pediatric BMT Unit, Çukurova University Medical School, Adana, Turkey
Search for more papers by this authorİlker Ünal
Department of Biostatistics, Çukurova University Medical School, Adana, Turkey
Search for more papers by this authorAyşe Özkan
Division of Pediatric Oncology & Pediatric BMT Unit, Çukurova University Medical School, Adana, Turkey
Search for more papers by this authorSerhan Küpeli
Division of Pediatric Oncology & Pediatric BMT Unit, Çukurova University Medical School, Adana, Turkey
Search for more papers by this authorİbrahim Bayram
Division of Pediatric Oncology & Pediatric BMT Unit, Çukurova University Medical School, Adana, Turkey
Search for more papers by this authorAtila Tanyeli
Division of Pediatric Oncology & Pediatric BMT Unit, Çukurova University Medical School, Adana, Turkey
Search for more papers by this authorAbstract
Background
Advances in stem cell transplantation have resulted in improved outcomes.
Methods
This is a retrospective study aimed to analyze changes in patient profile, transplantation, graft characteristics, and outcome among 241 pediatric patients who received stem cell transplantation in a single center between 1993 and 2019.
Results
In the 2010–2019, compared with the 1993–2009 period, a significantly higher 5-year overall survival (60% vs. 44%, p = .022) and an event-free survival (53% vs. 34%, p = .025) were observed. Cumulative incidence of deaths due to relapse or progression between the 1993–2009 and 2010–2019 periods were 33% and 26% respectively (p = .66). Cumulative incidence of non-relapse mortality was significantly higher during the 1993–2009 period compared with the 2010–2019 period for malignant diseases (57.7% vs. 28.3%, p = .007). The overall survival from acute graft-versus-host disease between 1993 and 2009 was 11% versus 46% between 2010 and 2019 (p = .0001). The overall survival from infection in both eras did not show any difference (p = .41).
Conclusions
Development in transplantation technology has led to a decrease in non-relapse mortality and better control of graft-versus-host disease. However, relapse and infection remained as major causes of death. Studies evaluating institutional trends in patients undergoing HSCT and analyzing their mortality profile, can improve the management of patients, leading to a reduction in transplant-related problems.
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
REFERENCES
- 1Horowitz MM. Thomas' Hematopoietic Cell Transplantation. John Wiley & Sons; 2016: 6.
- 2Passweg JR, Baldomero H, Peters C, et al. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant. 2014; 49(6): 744-750. doi:10.1038/bmt.2014.55
- 3Bolon YT, Atshan R, Allbee-Johnson M, Estrada-Merly N, Lee SJ. Current Use and Outcome of Hematopoietic Stem Cell Transplantation: CIBMTR Summary Slides, 2022. https://cibmtr.org/CIBMTR/Resources/Summary-Slides-Reports
- 4Davies SM, Ramsay NK, Klein JP, et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol. 2000; 18(2): 340-347. doi:10.1200/JCO.2000.18.2.340
- 5Satwani P, Jin Z, Duffy D, et al. Transplantation-related mortality, graft failure, and survival after reduced-toxicity conditioning and allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients. Biol Blood Marrow Transplant. 2013; 19(4): 552-561. doi:10.1016/j.bbmt.2012.12.005
- 6Pulsipher MA, Boucher KM, Wall D, et al. Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the pediatric blood and marrow transplant consortium study ONC0313. Blood. 2009; 114(7): 1429-1436. doi:10.1182/blood-2009-01-196303
- 7Bitan M, He W, Zhang MJ, et al. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Blood. 2014; 123(10): 1615-1620. doi:10.1182/blood-2013-10-535716
- 8Nash RA, Johnston L, Parker P, et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2005; 11(7): 495-505. doi:10.1016/j.bbmt.2005.03.006
- 9Gagliardi TA, Milner J, Cairo MS, Steinberg A. Concomitant Ruxolitinib and Ibrutinib for Graft-Versus-Host Disease (GVHD): The First Reported Use in Pediatric Patients. Cureus. 2022; 14(9):e29195. doi:10.7759/cureus.29195
- 10DiMaggio E. Acute graft-versus-host disease: emerging insights and updates into detection, prevention, and treatment. Pharmacotherapy. 2020; 40(8): 788-807. doi:10.1002/phar.2436
- 11Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015; 29(10): 2062-2068. doi:10.1038/leu.2015.212
- 12Rashidi A, DeFor TE, Holtan SG, Blazar BR, Weisdorf DJ, MacMillan ML. Outcomes and predictors of response in steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2019; 25(11): 2297-2302. doi:10.1016/j.bbmt.2019.07.017
- 13Jacobsohn DA, Vogelsang GB. Anti-cytokine therapy for the treatment of graft-versus-host disease. Curr Pharm des. 2004; 10(11): 1195-1205. doi:10.2174/1381612043452569
- 14Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007; 110(13): 4576-4583. doi:10.1182/blood-2007-06-097386
- 15Jardim TAP, Jardim BA, Breda GL, Bonfim C, Raboni SM. Mortality among pediatric hematopoietic stem cell transplantation patients: report from a single center in southern Brazil. Pediatr Transplant. 2021; 25(5):e13944. doi:10.1111/petr.13944
- 16Styczyński J, Tridello G, Koster L, et al. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transplant. 2020; 55(1): 126-136. doi:10.1038/s41409-019-0624-z
- 17Brissot E, Rialland F, Cahu X, et al. Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution. Bone Marrow Transplant. 2016; 51(2): 267-272. doi:10.1038/bmt.2015.250
- 18Hazar V, Karasu G, Uygun V, Akcan M, Küpesiz A, Yeşilipek A. Hematopoietic stem cell transplantation activity and trends at a pediatric transplantation center in Turkey during 1998-2008. Turk J Haematol. 2012; 29(2): 143-149. doi:10.5505/tjh.2012.78300
- 19Khan S, Siddiqui K, ElSolh H, et al. Outcomes of blood and marrow transplantation in children less than 2-years of age: 23 years of experience at a single center. Int J Pediatr Adolesc Med. 2022; 9(4): 190-195. doi:10.1016/j.ijpam.2022.09.002
- 20Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974; 18(4): 295-304. doi:10.1097/00007890-197410000-00001
- 21Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980; 69(2): 204-217. doi:10.1016/0002-9343(80)90380-0
- 22Ljungman P, Bregni M, Brune M, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant. 2010; 45(2): 219-234. doi:10.1038/bmt.2009.141
- 23Testi AM, Moleti ML, Angi A, Bianchi S, Barberi W, Capria S. Pediatric autologous hematopoietic stem cell transplantation: safety, efficacy, and patient outcomes. Literature Review. Pediatric Health Med Ther. 2023; 14: 197-215.
- 24Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study [published correction appears in J Clin Oncol. 2014 Jun 10;32(17):1862–3]. J Clin Oncol. 2009; 27(7): 1007-1013. doi:10.1200/JCO.2007.13.8925
- 25Guzelgul F, Seydel GS, Aksoy K. β-Globin gene mutations in pediatric patients with β-thalassemia in the region of Çukurova. Turkey Hemoglobin. 2020; 44(4): 249-253. doi:10.1080/03630269.2020.1792489
- 26Boztug H, Zecca M, Sykora KW, et al. Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia. Ann Hematol. 2015; 94(2): 297-306. doi:10.1007/s00277-014-2196-8
- 27Willasch AM, Peters C, Sedláček P, et al. Myeloablative conditioning for Allo-HSCT in pediatric ALL: FTBI or chemotherapy? A multicenter EBMT-PDWP study [published correction appears in bone marrow transplant. 2021 Oct;56(10):2615]. Bone Marrow Transplant. 2020; 55(8): 1540-1551. doi:10.1038/s41409-020-0854-0
- 28Peters C, Dalle JH, Locatelli F, et al. Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study. J Clin Oncol. 2021; 39(4): 295-307. doi:10.1200/JCO.20.02529
- 29Mateos MK, O'Brien TA, Oswald C, et al. Transplant-related mortality following allogeneic hematopoeitic stem cell transplantation for pediatric acute lymphoblastic leukemia: 25-year retrospective review. Pediatr Blood Cancer. 2013; 60(9): 1520-1527. doi:10.1002/pbc.24559
- 30Gatza E, Reddy P, Choi SW. Prevention and treatment of acute graft-versus-host disease in children, adolescents, and young adults. Biol Blood Marrow Transplant. 2020; 26(5): e101-e112. doi:10.1016/j.bbmt.2020.01.004
- 31Haroun E, Agrawal K, Leibovitch J, et al. Chronic graft-versus-host disease in pediatric patients: differences and challenges. Blood Rev. 2023; 60:101054. doi:10.1016/j.blre.2023.101054
- 32Woodard P, Tong X, Richardson S, et al. Etiology and outcome of graft failure in pediatric hematopoietic stem cell transplant recipients. J Pediatr Hematol Oncol. 2003; 25(12): 955-959. doi:10.1097/00043426-200312000-00010
- 33Szmit Z, Gorczyńska E, Mielcarek-Siedziuk M, Ussowicz M, Owoc-Lempach J, Kałwak K. Veno-occlusive disease in children and adolescents after hematopoietic stem cell transplantation: did the modified Seattle criteria fit the characteristics of pediatric population? Adv Clin Exp Med. 2020; 29(3): 339-344. doi:10.17219/acem/115070
- 34Corbacioglu S, Carreras E, Ansari M, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Tranplant. 2017; 53(2): 138-145. doi:10.1038/bmt.2017.161
- 35Yeung TW, Chan WYK, Wong SCY, Lee PPW, Cheuk DKL, Leung W. Epidemiology, risk factors and outcome of bacterial, fungal, and viral infections in pediatric allogeneic and autologous hematopoietic stem cell transplantation recipients. Blood. 2022; 140(Supplement 1): 12829-12830. doi:10.1182/blood-2022-168397
10.1182/blood-2022-168397 Google Scholar
- 36 Number of Syrians in Turkey December 2021. Refugeees Association. https://multeciler.org.tr/eng/number-of-syrians-in-turkey-december-2021/
- 37Gurlek Gokcebay D, Küpeli S, Gürsel O, et al. Hematopoietic stem cell transplantation activities and HRQOL of refugee or asylum seeker children in Turkey: a multicenter study. Pediatr Transplant. 2022; 26(8):e14397. doi:10.1111/petr.14397
Citing Literature
